Dr. Peter E. Bressler, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 727
Licensed in Texas since 1990, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Arizona College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TX license H7702 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Medical City Plano Plano, TX
- Texas Health Presbyterian Hospital Dallas Dallas, TX
- Medical City Dallas Hospital Dallas, TX
Medical groups
- North Texas Endocrine Center, P.a. (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 727
- Services billed
- 3,417
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 866 | 402 |
| Blood glucose (sugar) test performed by hand-held instrument | 620 | 291 |
| Hemoglobin a1c level | 556 | 281 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 308 | 142 |
| Established patient office or other outpatient visit, 20-29 minutes | 264 | 241 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 156 | 28 |
| New patient office or other outpatient visit, 45-59 minutes | 131 | 131 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 113 | 24 |
| Ultrasound scan of head and neck soft tissue | 45 | 44 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Dallas, TX | 501 |
| Synthroid (levothyroxine sodium) Other prescribers in Dallas, TX | 331 |
| Metformin Hcl Other prescribers in Dallas, TX | 173 |
| Ozempic (semaglutide) Other prescribers in Dallas, TX | 164 |
| Jardiance (empagliflozin) Other prescribers in Dallas, TX | 146 |
| Mounjaro (tirzepatide) Other prescribers in Dallas, TX | 131 |
| Alendronate Sodium Other prescribers in Dallas, TX | 123 |
| Glipizide Other prescribers in Dallas, TX | 96 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Dallas, TX | 93 |
| Unithroid (levothyroxine sodium) Other prescribers in Dallas, TX | 86 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 41 payments worth $953 in total to this clinician.
| Neurocrine Biosciences, Inc. | $92.56 |
|---|---|
| Tandem Diabetes Care, Inc. | $92.38 |
| Corcept Therapeutics | $72.51 |
| Novo Nordisk Inc | $68.53 |
| Lilly USA, LLC | $66.75 |
| Cequr Corporation | $59.17 |
| Sanofi-aventis U.S. LLC | $58.98 |
| Amgen Inc. | $56.96 |
| Food and Beverage | $953 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 7 companies. The companies reported $686,715 in research payments for these studies, mostly to the institutions running them.
- A Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome
AstraZeneca UK Limited - A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Eli Lilly and Company · Completed · NCT06584916 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Dis…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.